DIRS.INFO The most relevant business & tech news

☆ Employers Cut Off Access to Weight-Loss Drugs for Workers
▼ + stars: | 2023-08-02 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/employers-cut-off-access-to-weight-loss-drugs-for-workers-cb277a44

Persons: Dow Jones

☆ U.K. Reviews Safety of Ozempic, Other Weight-Loss Drugs
▼ + stars: | 2023-07-26 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/u-k-reviews-safety-of-ozempic-other-weight-loss-drugs-76952d65

Persons: Dow Jones

☆ Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs
▼ + stars: | 2023-07-25 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/biogen-to-cut-roughly-11-of-workforce-to-focus-on-big-return-drugs-145b3f23

Persons: Dow Jones

☆ Biogen to Lay Off Roughly 11% of Workforce to Focus on Big-Return Drugs
▼ + stars: | 2023-07-25 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/biogen-to-cut-roughly-11-of-workforce-to-focus-on-big-return-drugs-145b3f23

Persons: Dow Jones

☆ The Drugs That Are Gaining on Ozempic
▼ + stars: | 2023-07-05 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Persons: Dow Jones

☆ The Drugs That Are Gaining On Ozempic
▼ + stars: | 2023-06-27 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Persons: Dow Jones

☆ No More Shots: Pill Versions of Ozempic-Like Drugs Are Coming
▼ + stars: | 2023-06-25 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/no-more-shots-pill-versions-of-ozempic-like-drugs-are-coming-ca286ca2

Persons: Dow Jones

☆ After Illumina CEO’s Fall, Other Executives Are Expected to Take Hard Look at Deals
▼ + stars: | 2023-06-12 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/after-illumina-ceos-fall-other-executives-are-expected-to-take-hard-look-at-deals-c95c9e8

Persons: Dow Jones

☆ Illumina CEO Francis deSouza Resigns Amid Regulatory Hurdles, Proxy Fight
▼ + stars: | 2023-06-11 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Persons: Dow Jones, francis, desouza

☆ Blood-Test Customers Mistakenly Told They May Have Cancer
▼ + stars: | 2023-06-03 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/blood-test-customers-mistakenly-told-they-may-have-cancer-31baf9ea

Persons: Dow Jones

☆ Her son said his stepdad was sexually abusive. A judge gave the stepdad custody anyway. Then she found the photographs.
▼ + stars: | 2023-05-18 | by ( Olivia Gentile | ) www.businessinsider.com time to read: +58 min

Robert confronted Winenger with the allegations that November, and within weeks Winenger denied the claims in family court. In a family court hearing in Vista, California, on October 28, 2021, Commissioner Patti Ratekin chastised Jill Montes for allegedly alienating her kids from her ex-husband. From a list provided by the Delaware Family Court, Kelly chose a psychologist, William Northey. Their father cited the report in asking a Delaware family court judge to order the boys to change schools. Family Court of the State of Delaware, New Castle CountyCiting the email and a subsequent report, Michael pressed Ostroski to order the transfer.

Persons: he'd, Robert, stepdad, Thomas Winenger, Winenger, Robert's, Jill Montes, Montes, Patti Ratekin, she'd, Ratekin, Richard Gardner, Gardner, Lynn Steinberg, she's, Maya, shrieks, Joan Meier, They'd, —, Meier, Tom Brenner, Paige, Maggie Shannon, Claire, Eden, Weeks, Hester Prynne, Mitra Sarkhosh, Sarkhosh, San Diego Robert, Tom Winenger, Tamatha Clemens, Miguel Alvarez, Alvarez, overreact, Alvarez didn't, Bridges, Janell Ostroski, Linda Gottlieb, Ostroski, Michael D, Ashton, Alfield Reeves, Michael, Kelly D, Kelly, who've, Randy Rand, Chris, Rand, he's, Rand isn't, Jane Shatz of, Joann Murphey, Murphey, Steinberg, Ally Toyos, Kit R, Toyos, Emily, Richard Warshak, Elizabeth Loftus, Harvey Weinstein's, Loftus, Hannah Rodriguez, Linda Gottlieb's, Gottlieb, Rodriguez, Yvonne Parnell, Brian Ludmer, Ludmer, Parnell, aren't, Daniel Barrozo, Mom, Jean Mercer, Mercer, who'd, Michael Saini, Saini, Hannah Yoon, — Ashton, Judge Ostroski, William Northey, Northey, O, Addie Asay, mistreating Ashton, Rachel Brandenburg, Brandenburg, I've, Michael's, Gardner's, Gardner dosed, Dr, Paul Fink, Fink, Warshak, William Bernet, Patrick Clancy, doesn't, She'd, Brian Fitzpatrick, Sen, Susan Rubio, Meier's, Rebecca Connolly, didn't, Connolly, Heidi Simonson, Rubio, Theresa Manzella Organizations: Investigations, San, Business, Child Welfare, of, American Psychiatric Association, World Health Organization, American Professional Society, George Washington University, Violence Law, George Washington University Law School, Columbia University, PAS, Sarkhosh, San Diego County Sheriff's Department, California Health, Welfare Agency, Psychology, Bridges, Texas, Roane, Stockton University, University of Toronto, Families, Delaware Family Court, Family, Delaware Family, Association of Family, Conciliation, Newsday, University of Texas Southwestern Medical Center, HarperCollins, Family Bridges, Vanderbilt University, Disorders, The Justice Department, WHO, of Social Welfare, Family Law, Winenger, Montes, Superior Locations: San Diego County, Vista , California, of California, Family Bridges, United States, Santa Cruz , California, Sacramento, Los Angeles, San Diego, toddlerhood, Ratekin, San, California, Eden, New Castle County , Delaware, New York, Ashton, Delaware, Jane Shatz of California, Seattle, Southern California, Texas, Kansas, Toyos, Bozeman , Montana, Family, Tampa , Florida, New, Hudson Valley, Chino , California, Wilmington , Delaware, of Delaware, New Castle County, Denver, Washington, Pennsylvania, Susan Rubio of Los Angeles County, statehouses, Watsonville , California, Santa Cruz, Michigan , Kansas, Utah, Colorado, Montana

☆ How to Get Your Health Insurance to Cover Ozempic and Other Drugs Used for Weight Loss
▼ + stars: | 2023-05-15 | by ( Anna Wilde Mathews | Peter Loftus | ) www.wsj.com time to read: 1 min

If you want to take one of the buzzy drugs like Ozempic or Wegovy to lose weight, the toughest part may be finding a way to pay for it. Insurers and employers, fearing the cost of medications that list for $900 or more a month, often put up hurdles when patients seek access to one of the drugs to slim down. Yet there are ways to get your health plan to pay for your prescription, if you qualify—and some alternatives if you don’t.

☆ Why You Might Not Be Able to Start Taking Wegovy
▼ + stars: | 2023-05-04 | by ( Dominic Chopping | Peter Loftus | ) www.wsj.com time to read: 1 min

Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth SmelovThe Danish pharmaceutical giant that makes the obesity drug Wegovy said it would temporarily hold back some lower-strength starter doses in the U.S. in an effort to safeguard supplies for current patients amid soaring demand. The Food and Drug Administration cleared Wegovy, made by Novo Nordisk , as a treatment for chronic weight management in 2021. It has since exploded in popularity.

☆ Experimental Drug Slows Alzheimer’s in Large Study, Eli Lilly Says
▼ + stars: | 2023-05-03 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Eli Lilly’s Alzheimer’s drug targets a substance that forms plaque in the brain. Photo: Maddie McGarvey for The Wall Street JournalAn experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale. Based on the new data, Lilly said Wednesday it plans to apply this quarter to the U.S. Food and Drug Administration for approval to market the drug, setting up a potential agency decision later in 2023 or in 2024.

It is getting tougher for people taking expensive medicines to get financial help from drugmakers. Johnson & Johnson , Pfizer and other pharmaceutical companies are scaling back programs that cover the copayments of patients or provide free drugs. The programs have been costing drugmakers billions of dollars a year and have been increasing as health plans seeking to control their own spending have tried to take advantage of the assistance.

☆ Mounjaro Helps Diabetes Patients Lose ‘Meaningful’ Weight, Study Shows
▼ + stars: | 2023-04-27 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Illustration: Elizabeth SmelovEli Lilly & Co.’s drug Mounjaro for Type 2 diabetes helped people who are also overweight or obese lose up to 15.7% of their body weight, in a new study that could pave the way for Lilly to promote the drug as a weight-loss treatment. Indianapolis-based Lilly said that with the new data, it will complete in the coming weeks an application to the U.S. Food and Drug Administration to market Mounjaro as an anti-obesity treatment, which could enable an FDA decision by the end of the year.

☆ J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue Market
▼ + stars: | 2023-04-23 | by ( Corrie Driebusch | Peter Loftus | ) www.wsj.com time to read: 1 min

The division slated to become Kenvue generated $14.95 billion in global sales last year, about 15.7% of Johnson & Johnson’s total. Photo: BRENDAN MCDERMID/REUTERSJohnson & Johnson is poised to begin a roadshow to pitch shares of its consumer-healthcare business, the producer of household names such as Tylenol, in a test for an IPO market that has been in the doldrums for the past year. Kenvue Inc. plans to start meeting with prospective investors as early as Monday, people familiar with the matter said. The goal is to raise $3.5 billion or more in the offering at a valuation close to $40 billion, the people said. IPO roadshows typically last anywhere from a few days to a week ahead of the stock’s trading debut.

☆ What Is Ozempic and Why Is It Such a Big Deal Right Now?
▼ + stars: | 2023-04-20 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Illustration: Elizabeth SmelovA drug approved by the Food and Drug Administration to treat people with Type 2 diabetes has ignited a craze among social-media influencers, the rich and famous and everyday people alike. Ozempic, made by Novo Nordisk A/S, has gained popularity for its off-label use, helping users drop excess pounds within a matter of months. Demand has soared for Ozempic as well its sister drug, Wegovy, and Eli Lilly & Co.’s Mounjaro. Ozempic’s main ingredient, known as semaglutide, is in Wegovy, which was approved by the FDA in 2021 to treat obesity. Lilly’s Mounjaro, whose main ingredient is tirzepatide, was approved by the FDA in 2022 to treat diabetes, though it has also been used for weight loss.

☆ ‘I Hate You, Kathie Lee Gifford!’ Ozempic Users Report Bizarre Dreams
▼ + stars: | 2023-04-18 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Chery McLemore was recently enjoying watching a parade of cows and bulls at a cattle auction with actor Matthew McConaughey. Then he started climbing atop the small pet llama she had brought, and she had to raise her voice to tell him to stop. “Fine, you can stay with your llama, I’m leaving!” Mr. McConaughey screamed before storming off.

☆ Johnson & Johnson Posts Higher Quarterly Sales, Raises 2023 Outlook
▼ + stars: | 2023-04-18 | by ( Peter Loftus | Will Feuer | ) www.wsj.com time to read: 1 min

Johnson & Johnson is spinning off its consumer-health business into a company that will house well-known brands such as Tylenol. Johnson & Johnson raised its full-year sales and earnings outlook after revenue rose 5.6% in the first quarter, lifted by demand for everything from Tylenol to the company’s pharmaceutical products and contact lenses. The New Brunswick, N.J., healthcare-products company also said Tuesday that first-quarter earnings were largely wiped out by a $6.9 billion charge tied to J&J’s proposal to resolve tens of thousands of lawsuits alleging injuries caused by its talc-containing powders including Johnson’s Baby Powder.

☆ Johnson & Johnson Seeks $9 Billion Settlement of Talc Lawsuits
▼ + stars: | 2023-04-05 | by ( Peter Loftus | Andrew Scurria | ) www.wsj.com time to read: 1 min

Johnson & Johnson has proposed paying at least $8.9 billion to thousands of people who sued the company alleging that their use of J&J’s talc-containing powders caused cancer, in what would be one of the biggest product-liability settlements ever. The company also said Tuesday its LTL Management LLC unit, which J&J had established to deal with the litigation, has refiled for bankruptcy protection to seek approval of the plan to make the payments over 25 years.

☆ Johnson & Johnson Proposes Paying $9 Billion to Settle Talc Lawsuits
▼ + stars: | 2023-04-04 | by ( Peter Loftus | Andrew Scurria | ) www.wsj.com time to read: 1 min

Johnson & Johnson has stopped selling versions of Johnson’s Baby Powder that contain talc in the U.S. and Canada. Johnson & Johnson said it has proposed to pay at least $8.9 billion to thousands of people who sued the company alleging that their use of J&J’s talc-containing powders caused cancer, in what would be one of the biggest product-liability settlements ever. The company said Tuesday its LTL Management LLC unit has refiled for bankruptcy protection to seek approval of a plan to pay $8.9 billion over 25 years. J&J said more than 60,000 claimants have committed to support the proposed resolution, which requires approval in bankruptcy court.

☆ FTC Rejects Illumina’s $7 Billion Deal for Cancer-Test Developer Grail
▼ + stars: | 2023-04-03 | by ( Jonathan D. Rockoff | Peter Loftus | ) www.wsj.com time to read: 1 min

San Diego-based Illumina was ordered to unwind its already completed acquisition. The Federal Trade Commission rejected Illumina Inc.’s $7 billion deal for cancer-test developer Grail Inc., saying that going ahead would hurt competition in one of the new frontiers of diagnostic medicine. The FTC on Monday ordered Illumina to unwind the proposed merger, reversing an administrative law judge’s ruling that supported the big medical testing company.

☆ The ‘King Kong’ of Weight-Loss Drugs Is Coming
▼ + stars: | 2023-04-03 | by ( Peter Loftus | Photographs Maddie Mcgarvey For The Wall Street Journal | ) www.wsj.com time to read: 1 min

People who are overweight are flocking to the drug Ozempic to slim down. Looming is an even more powerful weight-loss treatment. The drug Mounjaro helped a typical person with obesity who weighed 230 pounds lose up to 50 pounds during a test period of nearly 17 months.

☆ Moderna to Price Its Covid-19 Vaccine at $130 a Dose
▼ + stars: | 2023-03-22 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

The list price of Moderna’s Covid-19 vaccine is much higher than what the U.S. government has been paying. Moderna Inc. will price its Covid-19 vaccine at about $130 per dose when it shifts to commercial distribution of the shots later this year, much higher than what the federal government has paid. The plans could add to criticism of the company from lawmakers who are scheduled to explore the cost of the shots at a hearing Wednesday.

Search resuls for: "Loftus"

25 mentions found